Abstract
Splizimomab, an antibody that targets CD2, was studied in the treatment of T and natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use*
-
B-Lymphocytes / immunology
-
B-Lymphocytes / virology
-
Epstein-Barr Virus Infections / drug therapy
-
Epstein-Barr Virus Infections / immunology
-
Epstein-Barr Virus Infections / prevention & control*
-
Humans
-
Killer Cells, Natural / immunology
-
Lymphocyte Depletion
-
Lymphoproliferative Disorders / drug therapy
-
Lymphoproliferative Disorders / immunology
-
Lymphoproliferative Disorders / prevention & control*
-
Rituximab
-
T-Lymphocytes / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab